VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a research report issued on Sunday. The brokerage set a "sell" rating on the stock.

Several other analysts have also recently weighed in on the stock. Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reiterated a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a research report on Thursday, February 6th.

VolitionRx Stock Down 0.8 %

Shares of VNRX traded down $0.01 during midday trading on Friday, reaching $0.59. 85,956 shares of the stock were exchanged, compared to its average volume of 103,392. The stock's 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.65. The company has a market cap of $54.49 million, a P/E ratio of -1.63 and a beta of 1.20. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.10.

Insider Buying and Selling

In other VolitionRx news, Director Guy Archibald Innes bought 174,764 shares of VolitionRx stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction dated Monday, December 9th. The shares were acquired at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock valued at $204,212 over the last quarter. 12.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On VolitionRx

A number of hedge funds have recently made changes to their positions in the stock. Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Millennium Management LLC bought a new stake in VolitionRx during the 4th quarter worth approximately $36,000. Finally, Two Sigma Securities LLC bought a new position in VolitionRx during the 4th quarter worth $29,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.